View ValuationOpGen 将来の成長Future 基準チェック /06現在、 OpGenの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長23.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 16CapForce Inc. announced delayed 10-Q filingOn 05/15/2026, CapForce Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01CapForce Inc. announced delayed annual 10-K filingOn 03/31/2026, CapForce Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 28OpGen, Inc., Annual General Meeting, Feb 23, 2026OpGen, Inc., Annual General Meeting, Feb 23, 2026.お知らせ • Dec 06+ 1 more updateCapForce International Holdings Ltd., Subsidiary of OpGen, Inc. Approves Promotion of Christian-Laurent Bonte as Chief Executive Officer, Effective December 1, 2025OpGen, Inc. announced that on December 1, 2025, Mr. Christian-Laurent Bonte entered into a promotion letter with CapForce International Holdings Ltd. (CapForce), a limited liability company incorporated in Malaysia and wholly owned subsidiary of the Company, pursuant to which he will serve as Chief Executive Officer of CapForce (the “Promotion Letter”). Pursuant to the Promotion Letter, Mr. Bonte’s employment may be terminated by CapForce at any time by one (1) month written notice by CapForce. Mr. Bonte, age 49, was a member of the Board until July 17, 2025, when he resigned from the Board and was appointed, pursuant to an offer letter dated June 25, 2025 (the “Offer Letter”), the Head of the Digital Investment Banking Arm of CapForce International Holdings Ltd. (“CapForce”), a limited liability company incorporated in Malaysia and wholly owned subsidiary of the Company. Mr. Bonte will continue to leverage his rich investment banking experience in Hong Kong and Singapore with broad in-depth Hong Kong and U.S. capital market exposure. Mr. Bonte’s experience includes serving as the Executive Director at Meyzer Capital Management Pte Ltd, a management consulting and alternative investments platform, since March 2024, as the Founder and the Managing Director of Far Cap Pte Ltd, a corporate finance and technology investment firm, from December 2021 to March 2024, and as the Managing Director of ARC Capital Ltd, an investment bank with a presence in Asia and the United States, from August 2017 to December 2021. CapForce International Holdings Ltd. announced to offer Mr. Christian Bonte, the full time position of Head of Investment Banking Arm, reporting to CapForce CEO and working alongside CapForce COO. The position is offered on the following terms.お知らせ • Nov 15OpGen, Inc. announced delayed 10-Q filingOn 11/14/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15OpGen, Inc. announced delayed 10-Q filingOn 08/14/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17OpGen, Inc. announced delayed 10-Q filingOn 05/16/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01OpGen, Inc. announced delayed annual 10-K filingOn 03/31/2025, OpGen, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Dec 28OpGen Provides Nasdaq Minimum Stockholders’ Equity Requirement Non-Compliance UpdateOn December 19, 2024, despite OpGen, Inc. regaining short-term compliance with the minimum stockholders' equity requirement of the Nasdaq Capital Market (Nasdaq") pursuant to Nasdaq Listing Rule 5550(b)(1) after the deadline for such compliance granted to the Company prior to AEI Capital Ltd. acquiring a controlling interest in the Company, the Nasdaq Listing and Hearing Review Council (the Listing Council") affirmed the decision of the Nasdaq Hearings Panel (the Panel"). As previously disclosed, on August 16, 2024, the Company received written notice of the Panel's determination to effect a trading suspension and delisting of the Company's securities based upon the Company's continued non-compliance with the minimum stockholders' equity requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(b)(1) (the Stockholders' Equity Rule"). While the trading suspension was effective as of August 20, 2024, the Company had appealed the Panel's decision to the Listing Council. Although the Company continues to disagree with the Listing Council's decision, as a result of such decision, unless Nasdaq's Board of Directors determines to review such decision pursuant to Nasdaq Listing Rule 5825, Nasdaq will ultimately file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission (the Commission") that will remove the Company's securities from listing on Nasdaq. The filing of the Form 25 had been stayed pending the Company's appeal of the Panel's decision to the Listing Council. The Company's shares of common stock will continue trading on the OTC Markets under the symbol OPGN" following the filing of the Form 25 with the Commission. Consistent with the Listing Council's decision, the Listing Council welcomes the Company's application for relisting and the Company plans to apply for relisting with The Nasdaq Stock Market LLC after meeting the relevant Nasdaq listing requirements.お知らせ • Nov 15OpGen, Inc. announced delayed 10-Q filingOn 11/14/2024, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 23+ 1 more updateOpGen Receives a Letter from the Nasdaq Hearings Panel Determines to Deny its Request for Continued Listing on NasdaqAs previously disclosed on June 11, 2024, OpGen, Inc. (the ‘Company’) received a letter from the listing staff of The Nasdaq Stock Market LLC (‘Nasdaq’) that the Company was no longer in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(b)(1) (the ‘Stockholders’ Equity Rule’). The Stockholders’ Equity Rule requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 or to meet alternatives of market value of listed securities or net income from continuing operations, which the Company does not currently meet. In response to the letter, the Company submitted its plan to regain compliance with the Stockholders’ Equity Rule to the Nasdaq Hearings Panel (the ‘Panel’) and requested additional time to regain compliance with such rule. On August 16, 2024, following the Panel’s review of the Company’s plan to regain compliance, the Company received a letter (the ‘Notice’) indicating that the Panel had determined to deny the Company’s request for continued listing on Nasdaq. Pursuant to the Notice, based on the preliminary nature of the Company’s plan, the Panel determined that the Company did not provide a definitive plan evidencing its ability to achieve near- and long-term compliance with the Stockholders’ Equity Requirement. Unless the Company requests an appeal of the Panel’s determination by August 31, 2024, Nasdaq will file a Form 25 Notification of Delisting with the SEC, which will remove the Company’s securities from listing on the Nasdaq Capital Market. The Notice also provided that the Company’s securities will be suspended from trading on the Nasdaq Capital Market at the opening of business on August 20, 2024. The Company currently intends to timely appeal this determination by requesting that the Nasdaq Listing and Hearing Review Council review the decision of the Panel. Such appeal will stay the delisting of the Company’s securities with Nasdaq and the filing of the Form 25 pending the Panel’s decision until the resolution of such review. There can be no assurance that the Nasdaq Listing and Hearing Review Council will grant the Company’s request for continued listing on Nasdaq. The Company continues to pursue various steps to regain compliance with the Stockholders’ Equity Rule. Most recently, on August 19, 2024, pursuant to the previously disclosed settlement agreements (the ‘Settlement Agreements’) with each of the European Investment Bank, the Company’s senior creditor (the ‘EIB’), and Curetis GmbH, the Company’s subsidiary in insolvency (‘Curetis’), the Company paid and settled its outstanding indebtedness with the EIB and Curetis. The settlement agreement with the EIB also terminated that certain Guarantee and Indemnity Agreement, dated as of July 9, 2024 (the ‘Guarantee Agreement’), by and between the Company and EIB, pursuant to which the Company had guaranteed all of Curetis’ debt to EIB. The foregoing description of the Settlement Agreements does not purport to be complete and is qualified in its entirety by reference to the full text of such Settlement Agreements, which are filed as Exhibits 10.2 and 10.3, respectively, to this Current Report on Form 8-K and incorporated herein by reference. In addition, as described in Item 1.01 of this Current Report on Form 8-K, the Company entered into the Purchase Agreement on August 22, 2024, pursuant to which the Company may sell the Shares for aggregate gross proceeds of up to $3,000,000. The information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. As a result of such settlements and the Financing, the Company expects its increased stockholders’ equity will result in the Company regaining compliance with the Stockholders’ Equity Rule. The Company plans to pursue further steps to cause the Company to maintain ongoing compliance with the Stockholders’ Equity Rule. Notwithstanding the foregoing, there can be no assurance that the Company will be successful in its efforts to regain and maintain such compliance.お知らせ • Aug 22OpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI IndexOpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI Indexお知らせ • Aug 21OpGen, Inc.(OTCPK:OPGN) dropped from NASDAQ Composite IndexOpGen, Inc. has been dropped from the Nasdaq Composite Index.お知らせ • Aug 15OpGen, Inc. announced delayed 10-Q filingOn 08/14/2024, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.Reported Earnings • Jul 09First quarter 2024 earnings released: EPS: US$0.21 (vs US$12.53 loss in 1Q 2023)First quarter 2024 results: EPS: US$0.21 (up from US$12.53 loss in 1Q 2023). Revenue: US$168.1k (down 82% from 1Q 2023). Net income: US$272.8k (up US$6.01m from 1Q 2023).お知らせ • Jun 13OpGen Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on NasdaqAs previously disclosed, the listing staff of The Nasdaq Stock Market LLC (‘Nasdaq’) notified OpGen, Inc. (the ‘Company’) on June 5, 2023 that the Company’s common stock had failed to maintain a minimum bid price of $1.00 per share for the 30 consecutive business days preceding the date of such notice as required by Nasdaq Listing Rule 5550(a)(2) (the ‘Minimum Bid Price Rule’). In December 2023, the Company appealed such determination to a Nasdaq Hearings Panel, which in February 2024, granted the Company’s request for an additional period to regain compliance with the Minimum Bid Price Rule. On June 5, 2024, the Nasdaq Hearings Panel notified the Company that it had regained compliance with the Minimum Bid Price Rule. In addition, on June 5, 2024, the Company received a notice from Nasdaq stating that the Company is not in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 or to meet the alternatives of market value of listed securities or net income from continuing operations. The notice indicated that such delinquency serves as an additional basis for delisting the Company’s securities from Nasdaq. In accordance with the notice, the Company submitted its response to the Nasdaq Hearings Panel on June 11, 2024 regarding such delinquency and the Company’s plan to cure such delinquency. As with the prior notices received by the Company, the most recent notice from Nasdaq has no immediate effect on the listing of the Company’s securities on The Nasdaq Capital Market. There can be no assurance that the Nasdaq Hearings Panel will grant the Company additional time to cure such deficiency or, if additional time is granted, that the Company will be able to regain compliance with the requirements for continued listing.お知らせ • Jun 05Nasdaq Hearings Panel Grants Extension to OpGen, to Regain Compliance by July 8, 2024As previously disclosed in a Current Report on Form 8-K filed on May 24, 2024, OpGen, Inc. (the Company") received an additional notice from The Nasdaq Stock Market LLC (Nasdaq") indicating that the Company was delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the Form 10-Q") and was therefore not in compliance with Nasdaq Listing Rule 5250(c)(1). Following submission of the Company's plan to cure such delinquency, on May 29, 2024, the Nasdaq Hearings Panel granted the Company's request for continued listing subject to the Company filing its Form 10-Q by July 8, 2024. The Company plans to file its Form 10-Q as soon as practicable; however, no assurance can be given as to the definitive date on which such report will be filed.New Risk • Jun 04New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$12m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Shares are highly illiquid. Negative equity (-US$12m). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Market cap is less than US$10m (€2.95m market cap, or US$3.21m). Minor Risk Revenue is less than US$5m (US$3.4m revenue).New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$18m free cash flow). Shares are highly illiquid. Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Market cap is less than US$10m (€3.56m market cap, or US$3.86m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Revenue is less than US$5m (US$3.1m revenue).Board Change • May 28No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Member of Clinical Advisory Board Stefan Riedel is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、OpGen は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測MUN:6500 - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20241-10-6-6N/A6/30/20242-22-7-6N/A3/31/20243-27-11-10N/A12/31/20233-33-15-14N/A9/30/20233-26-18-17N/A6/30/20233-36-20-18N/A3/31/20233-36-21-20N/A12/31/20223-37-21-20N/A9/30/20223-41-21-20N/A6/30/20224-33-21-21N/A3/31/20224-34-23-22N/A12/31/20214-42-23-21N/A9/30/20214-35-27-25N/A6/30/20214-37-29-27N/A3/31/20214-37-27-26N/A12/31/20204-26-24-23N/A9/30/20204-22-20-20N/A6/30/20203-17-15-15N/A3/31/20203-13-11-11N/A12/31/20193-12-12-12N/A9/30/20193-14-11-11N/A6/30/20193-13-12-11N/A3/31/20193-14-12-12N/A12/31/20183-13-11-11N/A9/30/20183-13-12-11N/A6/30/20183-13N/A-12N/A3/31/20183-13N/A-12N/A12/31/20173-15N/A-14N/A9/30/20173-17N/A-16N/A6/30/20173-19N/A-16N/A3/31/20174-20N/A-18N/A12/31/20164-19N/A-17N/A9/30/20164-19N/A-16N/A6/30/20165-19N/A-19N/A3/31/20164-19N/A-16N/A12/31/20153-18N/A-14N/A9/30/20153-14N/A-13N/A6/30/20153-12N/A-7N/A3/31/20154-8N/A-6N/A12/31/20144-6N/A-5N/A9/30/20144-9N/A-5N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 6500の予測収益成長が 貯蓄率 ( 1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 6500の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 6500の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 6500の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 6500の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 6500の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/02/02 11:45終値2024/11/05 00:00収益2024/09/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CapForce Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Benjamin HaynorAlliance Global Partnersnull nullBrookline Capital MarketsNidhi SinghEdison Investment Research2 その他のアナリストを表示
お知らせ • May 16CapForce Inc. announced delayed 10-Q filingOn 05/15/2026, CapForce Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01CapForce Inc. announced delayed annual 10-K filingOn 03/31/2026, CapForce Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 28OpGen, Inc., Annual General Meeting, Feb 23, 2026OpGen, Inc., Annual General Meeting, Feb 23, 2026.
お知らせ • Dec 06+ 1 more updateCapForce International Holdings Ltd., Subsidiary of OpGen, Inc. Approves Promotion of Christian-Laurent Bonte as Chief Executive Officer, Effective December 1, 2025OpGen, Inc. announced that on December 1, 2025, Mr. Christian-Laurent Bonte entered into a promotion letter with CapForce International Holdings Ltd. (CapForce), a limited liability company incorporated in Malaysia and wholly owned subsidiary of the Company, pursuant to which he will serve as Chief Executive Officer of CapForce (the “Promotion Letter”). Pursuant to the Promotion Letter, Mr. Bonte’s employment may be terminated by CapForce at any time by one (1) month written notice by CapForce. Mr. Bonte, age 49, was a member of the Board until July 17, 2025, when he resigned from the Board and was appointed, pursuant to an offer letter dated June 25, 2025 (the “Offer Letter”), the Head of the Digital Investment Banking Arm of CapForce International Holdings Ltd. (“CapForce”), a limited liability company incorporated in Malaysia and wholly owned subsidiary of the Company. Mr. Bonte will continue to leverage his rich investment banking experience in Hong Kong and Singapore with broad in-depth Hong Kong and U.S. capital market exposure. Mr. Bonte’s experience includes serving as the Executive Director at Meyzer Capital Management Pte Ltd, a management consulting and alternative investments platform, since March 2024, as the Founder and the Managing Director of Far Cap Pte Ltd, a corporate finance and technology investment firm, from December 2021 to March 2024, and as the Managing Director of ARC Capital Ltd, an investment bank with a presence in Asia and the United States, from August 2017 to December 2021. CapForce International Holdings Ltd. announced to offer Mr. Christian Bonte, the full time position of Head of Investment Banking Arm, reporting to CapForce CEO and working alongside CapForce COO. The position is offered on the following terms.
お知らせ • Nov 15OpGen, Inc. announced delayed 10-Q filingOn 11/14/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15OpGen, Inc. announced delayed 10-Q filingOn 08/14/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17OpGen, Inc. announced delayed 10-Q filingOn 05/16/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01OpGen, Inc. announced delayed annual 10-K filingOn 03/31/2025, OpGen, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Dec 28OpGen Provides Nasdaq Minimum Stockholders’ Equity Requirement Non-Compliance UpdateOn December 19, 2024, despite OpGen, Inc. regaining short-term compliance with the minimum stockholders' equity requirement of the Nasdaq Capital Market (Nasdaq") pursuant to Nasdaq Listing Rule 5550(b)(1) after the deadline for such compliance granted to the Company prior to AEI Capital Ltd. acquiring a controlling interest in the Company, the Nasdaq Listing and Hearing Review Council (the Listing Council") affirmed the decision of the Nasdaq Hearings Panel (the Panel"). As previously disclosed, on August 16, 2024, the Company received written notice of the Panel's determination to effect a trading suspension and delisting of the Company's securities based upon the Company's continued non-compliance with the minimum stockholders' equity requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(b)(1) (the Stockholders' Equity Rule"). While the trading suspension was effective as of August 20, 2024, the Company had appealed the Panel's decision to the Listing Council. Although the Company continues to disagree with the Listing Council's decision, as a result of such decision, unless Nasdaq's Board of Directors determines to review such decision pursuant to Nasdaq Listing Rule 5825, Nasdaq will ultimately file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission (the Commission") that will remove the Company's securities from listing on Nasdaq. The filing of the Form 25 had been stayed pending the Company's appeal of the Panel's decision to the Listing Council. The Company's shares of common stock will continue trading on the OTC Markets under the symbol OPGN" following the filing of the Form 25 with the Commission. Consistent with the Listing Council's decision, the Listing Council welcomes the Company's application for relisting and the Company plans to apply for relisting with The Nasdaq Stock Market LLC after meeting the relevant Nasdaq listing requirements.
お知らせ • Nov 15OpGen, Inc. announced delayed 10-Q filingOn 11/14/2024, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 23+ 1 more updateOpGen Receives a Letter from the Nasdaq Hearings Panel Determines to Deny its Request for Continued Listing on NasdaqAs previously disclosed on June 11, 2024, OpGen, Inc. (the ‘Company’) received a letter from the listing staff of The Nasdaq Stock Market LLC (‘Nasdaq’) that the Company was no longer in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(b)(1) (the ‘Stockholders’ Equity Rule’). The Stockholders’ Equity Rule requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 or to meet alternatives of market value of listed securities or net income from continuing operations, which the Company does not currently meet. In response to the letter, the Company submitted its plan to regain compliance with the Stockholders’ Equity Rule to the Nasdaq Hearings Panel (the ‘Panel’) and requested additional time to regain compliance with such rule. On August 16, 2024, following the Panel’s review of the Company’s plan to regain compliance, the Company received a letter (the ‘Notice’) indicating that the Panel had determined to deny the Company’s request for continued listing on Nasdaq. Pursuant to the Notice, based on the preliminary nature of the Company’s plan, the Panel determined that the Company did not provide a definitive plan evidencing its ability to achieve near- and long-term compliance with the Stockholders’ Equity Requirement. Unless the Company requests an appeal of the Panel’s determination by August 31, 2024, Nasdaq will file a Form 25 Notification of Delisting with the SEC, which will remove the Company’s securities from listing on the Nasdaq Capital Market. The Notice also provided that the Company’s securities will be suspended from trading on the Nasdaq Capital Market at the opening of business on August 20, 2024. The Company currently intends to timely appeal this determination by requesting that the Nasdaq Listing and Hearing Review Council review the decision of the Panel. Such appeal will stay the delisting of the Company’s securities with Nasdaq and the filing of the Form 25 pending the Panel’s decision until the resolution of such review. There can be no assurance that the Nasdaq Listing and Hearing Review Council will grant the Company’s request for continued listing on Nasdaq. The Company continues to pursue various steps to regain compliance with the Stockholders’ Equity Rule. Most recently, on August 19, 2024, pursuant to the previously disclosed settlement agreements (the ‘Settlement Agreements’) with each of the European Investment Bank, the Company’s senior creditor (the ‘EIB’), and Curetis GmbH, the Company’s subsidiary in insolvency (‘Curetis’), the Company paid and settled its outstanding indebtedness with the EIB and Curetis. The settlement agreement with the EIB also terminated that certain Guarantee and Indemnity Agreement, dated as of July 9, 2024 (the ‘Guarantee Agreement’), by and between the Company and EIB, pursuant to which the Company had guaranteed all of Curetis’ debt to EIB. The foregoing description of the Settlement Agreements does not purport to be complete and is qualified in its entirety by reference to the full text of such Settlement Agreements, which are filed as Exhibits 10.2 and 10.3, respectively, to this Current Report on Form 8-K and incorporated herein by reference. In addition, as described in Item 1.01 of this Current Report on Form 8-K, the Company entered into the Purchase Agreement on August 22, 2024, pursuant to which the Company may sell the Shares for aggregate gross proceeds of up to $3,000,000. The information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. As a result of such settlements and the Financing, the Company expects its increased stockholders’ equity will result in the Company regaining compliance with the Stockholders’ Equity Rule. The Company plans to pursue further steps to cause the Company to maintain ongoing compliance with the Stockholders’ Equity Rule. Notwithstanding the foregoing, there can be no assurance that the Company will be successful in its efforts to regain and maintain such compliance.
お知らせ • Aug 22OpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI IndexOpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI Index
お知らせ • Aug 21OpGen, Inc.(OTCPK:OPGN) dropped from NASDAQ Composite IndexOpGen, Inc. has been dropped from the Nasdaq Composite Index.
お知らせ • Aug 15OpGen, Inc. announced delayed 10-Q filingOn 08/14/2024, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Reported Earnings • Jul 09First quarter 2024 earnings released: EPS: US$0.21 (vs US$12.53 loss in 1Q 2023)First quarter 2024 results: EPS: US$0.21 (up from US$12.53 loss in 1Q 2023). Revenue: US$168.1k (down 82% from 1Q 2023). Net income: US$272.8k (up US$6.01m from 1Q 2023).
お知らせ • Jun 13OpGen Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on NasdaqAs previously disclosed, the listing staff of The Nasdaq Stock Market LLC (‘Nasdaq’) notified OpGen, Inc. (the ‘Company’) on June 5, 2023 that the Company’s common stock had failed to maintain a minimum bid price of $1.00 per share for the 30 consecutive business days preceding the date of such notice as required by Nasdaq Listing Rule 5550(a)(2) (the ‘Minimum Bid Price Rule’). In December 2023, the Company appealed such determination to a Nasdaq Hearings Panel, which in February 2024, granted the Company’s request for an additional period to regain compliance with the Minimum Bid Price Rule. On June 5, 2024, the Nasdaq Hearings Panel notified the Company that it had regained compliance with the Minimum Bid Price Rule. In addition, on June 5, 2024, the Company received a notice from Nasdaq stating that the Company is not in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 or to meet the alternatives of market value of listed securities or net income from continuing operations. The notice indicated that such delinquency serves as an additional basis for delisting the Company’s securities from Nasdaq. In accordance with the notice, the Company submitted its response to the Nasdaq Hearings Panel on June 11, 2024 regarding such delinquency and the Company’s plan to cure such delinquency. As with the prior notices received by the Company, the most recent notice from Nasdaq has no immediate effect on the listing of the Company’s securities on The Nasdaq Capital Market. There can be no assurance that the Nasdaq Hearings Panel will grant the Company additional time to cure such deficiency or, if additional time is granted, that the Company will be able to regain compliance with the requirements for continued listing.
お知らせ • Jun 05Nasdaq Hearings Panel Grants Extension to OpGen, to Regain Compliance by July 8, 2024As previously disclosed in a Current Report on Form 8-K filed on May 24, 2024, OpGen, Inc. (the Company") received an additional notice from The Nasdaq Stock Market LLC (Nasdaq") indicating that the Company was delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the Form 10-Q") and was therefore not in compliance with Nasdaq Listing Rule 5250(c)(1). Following submission of the Company's plan to cure such delinquency, on May 29, 2024, the Nasdaq Hearings Panel granted the Company's request for continued listing subject to the Company filing its Form 10-Q by July 8, 2024. The Company plans to file its Form 10-Q as soon as practicable; however, no assurance can be given as to the definitive date on which such report will be filed.
New Risk • Jun 04New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$12m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Shares are highly illiquid. Negative equity (-US$12m). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Market cap is less than US$10m (€2.95m market cap, or US$3.21m). Minor Risk Revenue is less than US$5m (US$3.4m revenue).
New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$18m free cash flow). Shares are highly illiquid. Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Market cap is less than US$10m (€3.56m market cap, or US$3.86m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Revenue is less than US$5m (US$3.1m revenue).
Board Change • May 28No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Member of Clinical Advisory Board Stefan Riedel is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.